Thomas Hutson, DO, PharmD discusses the role of tivozanib in the treatment landscape for patients with renal cell carcinoma.
June 15th 2022
An overview of the treatment options available for patients with renal cell carcinoma (RCC).
Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.
June 22nd 2022
Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.
Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.
June 29th 2022
Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.
Trodelvy Lengthens Time to Disease Progression in Metastatic Breast Cancer
The Journey to a Healthy Lifestyle After Cancer
Getting Out of the Woods: Strategies to Cope With Fear of Cancer Recurrence
Cancer Made Me Appreciate the Small Things in Life